Vertex Pharmaceuticals Inc (VRTX)
456.95
+6.15
(+1.36%)
USD |
NASDAQ |
May 24, 16:00
456.87
-0.08
(-0.02%)
After-Hours: 20:00
Vertex Pharmaceuticals SG&A Expense (Annual): 1.137B for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.137B |
| December 31, 2022 | 944.70M |
| December 31, 2021 | 840.10M |
| December 31, 2020 | 770.50M |
| December 31, 2019 | 658.50M |
| December 31, 2018 | 557.62M |
| December 31, 2017 | 496.08M |
| December 31, 2016 | 432.83M |
| December 31, 2015 | 376.58M |
| December 31, 2014 | 305.41M |
| December 31, 2013 | 356.19M |
| December 31, 2012 | 432.68M |
| December 31, 2011 | 400.72M |
| December 31, 2010 | 187.80M |
| December 31, 2009 | 130.19M |
| December 31, 2008 | 101.29M |
| December 31, 2007 | 84.73M |
| Date | Value |
|---|---|
| December 31, 2006 | 57.86M |
| December 31, 2005 | 43.99M |
| December 31, 2004 | 42.14M |
| December 31, 2003 | 39.08M |
| December 31, 2002 | 41.06M |
| December 31, 2001 | 31.86M |
| December 31, 2000 | 41.35M |
| December 31, 1999 | 26.10M |
| December 31, 1998 | 18.10M |
| December 31, 1997 | 11.40M |
| December 31, 1996 | 22.90M |
| December 31, 1995 | 7.10M |
| December 31, 1994 | 40.30M |
| December 31, 1993 | 26.70M |
| December 31, 1992 | 13.80M |
| December 31, 1991 | 8.80M |
| December 31, 1990 | 6.40M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
658.50M
Minimum
2019
1.137B
Maximum
2023
870.08M
Average
840.10M
Median
2021
SG&A Expense (Annual) Benchmarks
| Eli Lilly and Co | 6.941B |
| Regeneron Pharmaceuticals Inc | 2.631B |
| Alpine Immune Sciences Inc (DELISTED) | 22.22M |
| Amgen Inc | 6.179B |
| Editas Medicine Inc | 69.65M |